Sun Pharma Prepares $12 Billion Bid for Organon in Biggest Overseas Pharma Deal by Indian Firm

Sun Pharmaceutical Industries is preparing a potential $12 billion bid to acquire US-based Organon, in what could become the largest overseas acquisition by an Indian pharmaceutical company, according to sources familiar with the matter. The move signals an aggressive global expansion strategy by India’s largest drugmaker amid increasing consolidation in the pharmaceutical sector.

The proposed transaction, still under discussion, would significantly expand Sun Pharma’s footprint in international markets, particularly in women’s health and off-patent branded medicines, which form a major part of Organon’s portfolio. If successful, the deal would mark a major milestone in India’s pharmaceutical industry.

Largest Overseas Acquisition Attempt by Indian Pharma

The planned bid is estimated at around $12 billion, making it the biggest cross-border acquisition attempt by an Indian pharmaceutical company to date. Industry analysts note that such a deal would surpass previous outbound acquisitions in the sector, reflecting the growing financial and strategic capabilities of Indian drugmakers.

Organon, a global healthcare company spun off from Merck & Co., focuses on women’s health, biosimilars, and established medicines. Its diversified portfolio and global presence make it an attractive target for companies seeking to scale operations internationally.

Sun Pharma’s interest in Organon aligns with its strategy to strengthen its specialty and complex generics business while diversifying revenue streams across geographies.

Strategic Focus on Women’s Health and Global Markets

A potential acquisition would provide Sun Pharma with immediate access to Organon’s established presence in women’s health, a segment that has seen increasing demand globally. This includes treatments across reproductive health, contraception, and menopause management.

In addition, Organon’s portfolio of off-patent branded drugs offers stable revenue streams, particularly in emerging markets where such products maintain strong demand.

The deal could also enhance Sun Pharma’s position in regulated markets such as the United States and Europe, while expanding its reach in developing regions.

Financing and Deal Structure Under Consideration

Sources indicate that Sun Pharma is evaluating multiple financing options for the proposed acquisition, including a mix of debt and internal accruals. Discussions are ongoing, and the final structure of the deal has yet to be determined.

The scale of the transaction would require careful financial planning, given the size of the investment and potential regulatory approvals across multiple jurisdictions.

Market observers note that large-scale acquisitions in the pharmaceutical sector often involve complex negotiations, due diligence processes, and approvals from competition authorities.

Industry Consolidation Driving M&A Activity

The global pharmaceutical industry has witnessed increasing consolidation in recent years, driven by the need to expand product pipelines, access new markets, and achieve operational efficiencies. Companies are increasingly pursuing mergers and acquisitions to remain competitive in a rapidly evolving landscape.

Indian pharmaceutical firms, traditionally focused on generic drug manufacturing, are now exploring opportunities in specialty medicines, biosimilars, and branded products through strategic acquisitions.

Sun Pharma’s potential bid reflects this shift, highlighting a move toward higher-value segments and global scale.

Deal Still in Early Stages

While discussions are underway, the proposed acquisition is still at an early stage and may not necessarily result in a final agreement. Both companies have not made any official announcements regarding the deal.

Industry experts caution that large transactions of this nature can face multiple hurdles, including valuation disagreements and regulatory scrutiny, which could impact timelines or outcomes.

If completed, the acquisition would represent a landmark moment for India’s pharmaceutical sector, underscoring its growing influence in the global healthcare industry.